

**FORM 2B**

**LISTING SUMMARY**

|  |  |                               |                               |                            |
|--|--|-------------------------------|-------------------------------|----------------------------|
| <b>Issuer Name: BioHarvest Sciences Inc.</b>   | <b>Listing Statement Date: April 17, 2020</b>  |                               |                               |                            |
| <b>Descriptions of securities to be listed: 410,301,419 common shares without par value.</b> |  |                               |                               |                            |
| <b>Address: Suite 1140 – 625 Howe Street, Vancouver, BC V6C 2T6</b>                          | <b>Brief Description of the Issuer's Business: Consumer Products - biotechnology/pharmaceuticals</b>   |                               |                               |                            |
| <b>Company Contact: David K. Ryan, President</b>   | <b>Description of securities outstanding</b>   |                               |                               |                            |
| <b>Phone: 604-622-1186</b>   | <b>Symbol<br/>BHSC</b>   | <b>Type<br/>common shares</b> | <b>Number<br/>410,301,419</b> | <b>CUSIP<br/>09076J108</b> |
| <b>Fax: 604-685-9182</b>   | <p>If the Listing Statement was required to be filed because an event giving rise to material information has occurred that makes the previous Statement inaccurate or misleading, briefly describe the event: Under an agreement and plan of merger dated Dec. 9, 2019 between the Issuer, BioHarvest Ltd. and the Issuer's Israeli subsidiary BioFarming Ltd. the Issuer acquired 100% of its controlling shareholder BioHarvest Ltd. by issuing 299,057,739 common shares at a deemed price of 15 cents per share to the shareholders of BioHarvest Ltd. The Issuer also issued 39,565,579 warrants to the holders of convertible debt of BioHarvest Ltd. who converted their debt to shares immediately prior to closing. The creditors' warrants, which are exercisable until Aug. 31, 2020, to purchase additional common shares at \$1 per share, replaced warrants the creditors were entitled to receive in BioHarvest Ltd. In addition, the Issuer granted 11,910,000 stock options to BioHarvest's and the Issuer's Chief Technology Officer. The options are exercisable to purchase shares of the Issuer at 15 cents per share for a period</p> |                               |                               |                            |

|   |                         |                       |   |           |
|---|-------------------------|-----------------------|---|-----------|
|   |                         |                       | of two years and will vest quarterly over that period.  |           |
| E-mail:dave.ryan@cannavcell.com                 |                         |                       | Dates of Press Release and Any Public Filings Concerning the Event:<br>Press Release -December 13, 2019<br>Information Circular – March 5, 2020<br>Form 2A Listing Statement - April 17, 2020 |           |
| Jurisdiction of Incorporation: British Columbia |                         |                       | Date of Last Shareholders' Meeting and Date of Next Shareholders' Meeting (if scheduled): January 2, 2020   |           |
| Website:N/A                                     |                         |                       |   |           |
| Fiscal Year End: December 31                    |                         |                       |   |           |
| Financial Information as at: January 31, 2020   |                         |                       | Board of Directors:<br>David K. Ryan<br>Zaki Rakib<br>Vivien Rakin<br>Liron Carmel  |           |
| In USD  | <u>January 31, 2020</u> | <u>April 30, 2019</u> | Name  | Position  |
| Current Assets                                  | \$177,000               | \$868,000             | <u>"David Ryan"</u><br>David K. Ryan  | President |
| Working Capital                                 | \$(294,000)             | \$841,000             | <u>"Alan Rootenberg"</u><br>Alan Rootenberg   | CFO       |
| Total assets                                    | \$4,934,000             | \$5,625,000           |   |           |
| Long-term liabilities                           | \$1,226,000             | \$1,881,000           |   |           |
| Shareholders' equity                            | \$3,237,000             | \$3,717,000           |   |           |